HK1205430A1 - Salts of an epidermal growth factor receptor kinase inhibitor - Google Patents

Salts of an epidermal growth factor receptor kinase inhibitor

Info

Publication number
HK1205430A1
HK1205430A1 HK15106102.5A HK15106102A HK1205430A1 HK 1205430 A1 HK1205430 A1 HK 1205430A1 HK 15106102 A HK15106102 A HK 15106102A HK 1205430 A1 HK1205430 A1 HK 1205430A1
Authority
HK
Hong Kong
Prior art keywords
salts
growth factor
kinase inhibitor
factor receptor
epidermal growth
Prior art date
Application number
HK15106102.5A
Other languages
English (en)
Chinese (zh)
Inventor
Mei Lai
Steven Richard Witowski
Richland Wayne Tester
Kwangho Lee
Original Assignee
Celgene Avilomics Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Res Inc filed Critical Celgene Avilomics Res Inc
Publication of HK1205430A1 publication Critical patent/HK1205430A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C07C309/27—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/02—Saturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15106102.5A 2012-03-15 2015-06-26 Salts of an epidermal growth factor receptor kinase inhibitor HK1205430A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611400P 2012-03-15 2012-03-15
PCT/US2013/030996 WO2013138502A1 (fr) 2012-03-15 2013-03-13 Sels d'inhibiteur de kinases du récepteur de facteur de croissance épidermique

Publications (1)

Publication Number Publication Date
HK1205430A1 true HK1205430A1 (en) 2015-12-18

Family

ID=49161781

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106102.5A HK1205430A1 (en) 2012-03-15 2015-06-26 Salts of an epidermal growth factor receptor kinase inhibitor

Country Status (28)

Country Link
US (5) US9108927B2 (fr)
EP (1) EP2825042B1 (fr)
JP (2) JP6317320B2 (fr)
KR (1) KR102090453B1 (fr)
CN (2) CN104284584B (fr)
AR (1) AR090357A1 (fr)
AU (3) AU2013201519C1 (fr)
BR (1) BR112014022790B1 (fr)
CA (1) CA2866857C (fr)
CY (1) CY1122176T1 (fr)
DK (1) DK2825042T3 (fr)
ES (1) ES2698298T3 (fr)
HK (1) HK1205430A1 (fr)
HR (1) HRP20181784T1 (fr)
IL (1) IL234426B (fr)
LT (1) LT2825042T (fr)
MX (1) MX356179B (fr)
MY (1) MY185243A (fr)
PH (1) PH12014502037B1 (fr)
PL (1) PL2825042T3 (fr)
PT (1) PT2825042T (fr)
RS (1) RS57901B1 (fr)
RU (1) RU2711077C9 (fr)
SG (2) SG10201700799WA (fr)
SI (1) SI2825042T1 (fr)
TR (1) TR201816244T4 (fr)
TW (1) TWI591060B (fr)
WO (1) WO2013138502A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201508958WA (en) 2010-11-01 2015-11-27 Celgene Avilomics Res Inc Heterocyclic Compounds And Uses Thereof
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
KR102090453B1 (ko) 2012-03-15 2020-03-19 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 염
CA2900012A1 (fr) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Inhibiteurs d'erk et leurs utilisations
US20160074399A1 (en) * 2013-05-06 2016-03-17 Clovis Oncology, Inc. Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
NO2718543T3 (fr) 2014-02-04 2018-01-06
WO2016025561A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formes et compositions d'un inhibiteur d'erk
WO2016101912A1 (fr) * 2014-12-25 2016-06-30 苏州晶云药物科技有限公司 Forme cristalline d'un sel d'un inhibiteur de kinase du récepteur du facteur de croissance épidermique et son procédé de préparation
CN104961688A (zh) * 2014-12-25 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体激酶抑制剂的磷酸盐及其制备方法
WO2017016463A1 (fr) * 2015-07-24 2017-02-02 上海海雁医药科技有限公司 Inhibiteur de l'egfr et sel pharmaceutiquement acceptable et polymorphe de celui-ci, et utilisation associée
CN105461640B (zh) * 2015-12-02 2017-11-21 芷威（上海）化学科技有限公司 一种酪氨酸激酶抑制剂的制备方法
CN105481779B (zh) * 2015-12-24 2019-01-25 南京华威医药科技集团有限公司 抗癌药物Rociletinib及其中间体制备
JOP20190281A1 (ar) * 2017-06-13 2019-12-02 Korea Res Inst Chemical Tech مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
AU2022324410A1 (en) * 2021-08-02 2024-01-18 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4032637A (en) 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4337341A (en) 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5453510A (en) 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
JPH0741461A (ja) 1993-05-27 1995-02-10 Eisai Co Ltd スルホン酸エステル誘導体
CA2214685C (fr) 1995-03-10 2008-05-20 Berlex Laboratories, Inc. Derives de benzamidine et utilisation de ces derives en tant qu'anticoagulants
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DE69839735D1 (de) 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
UA70966C2 (uk) 1998-11-10 2004-11-15 Янссен Фармацевтика Н.В. Піримідини, що інгібують реплікацію віл
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
US6127376A (en) 1998-12-04 2000-10-03 Berlex Laboratories, Inc. Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
AU2871900A (en) 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
KR20020016872A (ko) 1999-06-29 2002-03-06 사바 키스 ; 아틸라 만디 야노스 템페 ; 기울라 시미그 신규한 피페라지닐알킬티오피리미딘 유도체, 그것을함유하는 약제 조성물, 및 활성성분의 제조방법
JP4794793B2 (ja) 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
EP1257546A1 (fr) 2000-02-17 2002-11-20 Amgen Inc. Inhibiteurs de kinases
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1282607B1 (fr) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Promedicaments a base de pyrimidines inhibant la replication du vih
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US7427689B2 (en) 2000-07-28 2008-09-23 Georgetown University ErbB-2 selective small molecule kinase inhibitors
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
EA007298B1 (ru) 2001-11-01 2006-08-25 Янссен Фармацевтика Н.В. Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1472233A1 (fr) 2002-02-08 2004-11-03 SmithKline Beecham Corporation Composes de pyrimidine
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003228345B2 (en) 2002-03-21 2009-02-05 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
US20040002395A1 (en) 2002-06-27 2004-01-01 Poynor Raymond L. Bridge weight for metal wood golf club
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
CA2439440A1 (fr) 2002-09-05 2004-03-05 Emory University Traitement de tumeurs associees a la sclerose tubereuse
AU2002951853A0 (en) 2002-10-04 2002-10-24 Commonwealth Scientific And Industrial Research Organisation Crystal structure of erbb2 and uses thereof
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2004210081B2 (en) 2003-02-07 2009-11-26 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of HIV infection
ATE433447T1 (de) 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1656372B1 (fr) 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. Derives de 2,4-pyrimidinediamine pour le traitement ou la prevention de maladies auto-immunes
DE602004032446D1 (de) 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
MXPA06001759A (es) 2003-08-15 2006-05-12 Novartis Ag 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios.
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
AU2004272288B2 (en) 2003-09-18 2008-11-13 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1694652A1 (fr) 2003-12-19 2006-08-30 Rigel Pharmaceuticals, Inc. Stereoisomeres et melanges stereoisomeriques d'intermediaires synthetiques de 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide
PT1704145E (pt) 2004-01-12 2012-09-04 Ym Biosciences Australia Pty Inibidores de quinase seletivos
TW200526219A (en) 2004-01-16 2005-08-16 Wyeth Corp Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
EP1735268B1 (fr) 2004-03-15 2012-02-15 Eli Lilly And Company Antagonistes des recepteurs opioides
WO2005105988A2 (fr) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Structure cristalline de complexe de domaine jak3 kinase humaine et ses poches de liaison
CA2566531A1 (fr) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
EP1598343A1 (fr) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK
EP3042964A1 (fr) 2004-06-04 2016-07-13 Genentech, Inc. Mutations egfr
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
JP2008538544A (ja) 2004-09-23 2008-10-30 レディ ユーエス セラピューティックス， インコーポレイテッド 新規ピリミジン化合物、それらの調製のためのプロセスおよびそれらを含む組成物
US7531548B2 (en) 2004-09-30 2009-05-12 Tibotec Pharmaceuticals Ltd HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
GT200500286A (es) 2004-10-13 2006-06-13 Analogos de anilino-pirimidina
EP1805208A2 (fr) 2004-10-20 2007-07-11 Proteolix, Inc. Composés pour inhibition d'enzymes
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2594860A1 (fr) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Derives de cinnamide et d'hydrocinnamide presentant une activite inhibitrice de raf-kinase
PT1856135E (pt) 2005-01-19 2010-02-26 Rigel Pharmaceuticals Inc Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
CN101193905B (zh) 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
CN101155799A (zh) 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
US20060270694A1 (en) 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
WO2006124874A2 (fr) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2006128129A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Traitement anticancereux
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006129100A1 (fr) 2005-06-03 2006-12-07 Glaxo Group Limited Nouveaux composes
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
WO2007048065A2 (fr) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones en tant que modulateurs de caseine kinase ii (ck2)
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
AU2006311910A1 (en) 2005-11-03 2007-05-18 Irm Llc Protein kinase inhibitors
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
JP2009520038A (ja) 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド ピリミジンキナーゼインヒビター
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
CA2640398A1 (fr) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines ou 4-aryl-2-aminoalkyl-pyrimidines utilisees comme modulateurs de la jak-2 et leurs procedes d'utilisation
SI1984357T1 (sl) 2006-02-17 2014-02-28 Rigel Pharmaceuticals, Inc. Spojine 2,4-pirimidindiamina za zdravljenje ali preventivo avtoimunih bolezni
CA2642229C (fr) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions et methodes destinees a l'inhibition de la voie jak
CA2645959C (fr) 2006-03-30 2016-05-17 Tibotec Pharmaceuticals Ltd. Pyrimidines substituees 5-(hydroxymethylene et aminomethylene) inhibant le vih
CA2645958C (fr) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Pyrimidines a substitution 5-amido inhibant le vih
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
CA2650035C (fr) 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly(ethylene glycol) contenant des endogroupes chimiquement disparates
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
CA2656290A1 (fr) 2006-07-05 2008-01-10 Exelixis, Inc. Procedes d'utilisation de modulateurs de kinase igf1r et abl
US20100010025A1 (en) 2006-07-21 2010-01-14 Norvartis Ag Pyrimidine Derivatives
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
PL2529621T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
CA2673125C (fr) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
CA2673137C (fr) 2006-11-21 2015-02-10 Rigel Pharmaceuticals, Inc. Promedicaments de composes de 2,4-pyrimidinediamine et leurs utilisations
EP2091918B1 (fr) 2006-12-08 2014-08-27 Irm Llc Composés et compositions inhibant la protéine kinase
EP2099771A1 (fr) 2006-12-19 2009-09-16 Genentech, Inc. Inhibiteurs de pyrimidine kinase
EP1939185A1 (fr) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Nouveaux hetaryl-phénylènediamine-pyrimidines en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer
KR20090094073A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
EA020749B1 (ru) 2006-12-29 2015-01-30 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5,6-замещенные пиримидины
CL2008000197A1 (es) 2007-01-26 2008-08-01 Smithkline Beecham Corp Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
EP2114900B1 (fr) 2007-01-31 2018-10-10 YM BioSciences Australia Pty Ltd Composés à base de thiopyrimidine et ses utilisations
JP4221470B2 (ja) 2007-02-01 2009-02-12 トヨタ自動車株式会社 電動車両制御装置及び電動車両制御方法
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
MX2009010047A (es) 2007-03-20 2009-12-04 Smithkline Beecham Corp Compuestos quimicos.
CN101677554A (zh) 2007-03-20 2010-03-24 史密丝克莱恩比彻姆公司 化合物
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008118823A2 (fr) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions et procédés pour l'inhibition de la voie jak
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2152079A4 (fr) 2007-06-04 2011-03-09 Avila Therapeutics Inc Composés hétérocycliques et utilisations de ceux-ci
EP2183225A1 (fr) 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Pyrimidinediamines substituées par des amines cycliques utilisées en tant qu'inhibiteurs de la pkc
WO2009017838A2 (fr) 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
EA017252B1 (ru) 2007-08-28 2012-11-30 Айрм Ллк Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
US20090088371A1 (en) 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
WO2009032703A1 (fr) 2007-08-28 2009-03-12 Irm Llc Composés et compositions inhibiteurs de kinase
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
US20110028405A1 (en) 2007-12-20 2011-02-03 Richard John Harrison Sulfamides as zap-70 inhibitors
PL2252300T3 (pl) 2008-02-22 2017-04-28 Rigel Pharmaceuticals, Inc. Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy
CA2717529A1 (fr) 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides en tant qu'inhibiteurs de zap-70
US8205348B2 (en) 2008-03-19 2012-06-26 Zashiki-Warashi Manufacturing Inc. Tile spacer and holder therefor
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
WO2009127642A2 (fr) 2008-04-15 2009-10-22 Cellzome Limited Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2274288A2 (fr) 2008-04-24 2011-01-19 Incyte Corporation Composés macrocycliques et leur utilisation à titre d'inhibiteurs de kinase
EA029131B1 (ru) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
MX2010014029A (es) 2008-06-27 2011-01-21 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
EA201100439A1 (ru) 2008-09-03 2011-12-30 Байер Кропсайенс Аг Анилинопиримидины, замещенные группами алкокси и алкилтио
WO2010077740A2 (fr) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Nouveaux composés antiviraux, compositions et procédés d'utilisation
JP2012514985A (ja) 2009-01-15 2012-07-05 エフ．ホフマン−ラ ロシュ アーゲー ヒトｅｐｏ受容体に対する抗体
ES2423804T3 (es) 2009-04-03 2013-09-24 Cellzome Gmbh Métodos para la identificación de moléculas que interaccionan con cinasas y para la purificación de proteínas de cinasa
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
EP3009428B1 (fr) 2009-05-08 2018-02-21 Astellas Pharma Inc. Composés de carboxamide hétérocycliques diamino
EP2443095A1 (fr) 2009-06-18 2012-04-25 Cellzome Limited Sulfonamides et sulfamides servant d'inhibiteurs de la zap-70
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011079231A1 (fr) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Composés qui modulent l'activité egfr et des procédés pour traiter ou prévenir des affections avec ceux-ci
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
AU2011261185A1 (en) 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
WO2011153553A2 (fr) 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
SG10201508958WA (en) 2010-11-01 2015-11-27 Celgene Avilomics Res Inc Heterocyclic Compounds And Uses Thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2012255759B2 (en) 2011-05-17 2017-08-10 Principia Biopharma, Inc. Kinase inhibitors
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
KR102090453B1 (ko) 2012-03-15 2020-03-19 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 염
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
US20160074399A1 (en) 2013-05-06 2016-03-17 Clovis Oncology, Inc. Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor

Also Published As

Publication number Publication date
KR102090453B1 (ko) 2020-03-19
AU2018201896A1 (en) 2018-04-12
PT2825042T (pt) 2018-11-16
TR201816244T4 (tr) 2018-11-21
EP2825042B1 (fr) 2018-08-01
MY185243A (en) 2021-04-30
ES2698298T3 (es) 2019-02-04
US20190152925A1 (en) 2019-05-23
CY1122176T1 (el) 2020-07-31
AR090357A1 (es) 2014-11-05
AU2013201519C1 (en) 2016-06-23
RU2711077C2 (ru) 2020-01-15
SG11201405692UA (en) 2014-10-30
AU2013201519B2 (en) 2016-02-25
CN109053595A (zh) 2018-12-21
PL2825042T3 (pl) 2019-02-28
RU2014136893A (ru) 2016-05-10
RU2711077C9 (ru) 2020-08-11
US9108927B2 (en) 2015-08-18
SG10201700799WA (en) 2017-02-27
US11292772B2 (en) 2022-04-05
TW201341372A (zh) 2013-10-16
US20130267531A1 (en) 2013-10-10
US9540335B2 (en) 2017-01-10
LT2825042T (lt) 2018-12-10
US20210017137A1 (en) 2021-01-21
CN104284584B (zh) 2019-06-04
AU2016203343A1 (en) 2016-06-16
JP2018024708A (ja) 2018-02-15
JP2015510890A (ja) 2015-04-13
CN109053595B (zh) 2022-04-01
SI2825042T1 (sl) 2019-01-31
WO2013138502A1 (fr) 2013-09-19
DK2825042T3 (en) 2018-11-26
PH12014502037A1 (en) 2014-11-24
MX356179B (es) 2018-05-17
RS57901B1 (sr) 2019-01-31
BR112014022790B1 (pt) 2022-04-19
MX2014010848A (es) 2014-12-10
EP2825042A4 (fr) 2015-09-23
BR112014022790A2 (fr) 2017-06-20
EP2825042A1 (fr) 2015-01-21
CA2866857C (fr) 2021-03-09
US10570099B2 (en) 2020-02-25
IL234426B (en) 2018-07-31
CA2866857A1 (fr) 2013-09-19
AU2018201896B2 (en) 2019-10-31
AU2013201519A1 (en) 2013-10-03
JP6317320B2 (ja) 2018-04-25
US20170217904A1 (en) 2017-08-03
HRP20181784T1 (hr) 2018-12-28
US20150344441A1 (en) 2015-12-03
TWI591060B (zh) 2017-07-11
CN104284584A (zh) 2015-01-14
US10005738B2 (en) 2018-06-26
KR20140138941A (ko) 2014-12-04
JP6676602B2 (ja) 2020-04-08
PH12014502037B1 (en) 2014-11-24

Similar Documents

Publication Publication Date Title
HRP20181784T1 (hr) Soli epidermalnog faktora rasta inhibitora receptora kinaze
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
HK1205431A1 (en) Solid forms of an epidermal growth factor receptor kinase inhibitor
HK1216315A1 (zh) 表皮生長因子受體的活化突變形式的喹唑啉抑制劑
HK1206023A1 (en) Inhibitors of the fibroblast growth factor receptor
SI2710005T1 (sl) Zaviralci tirozinske kinaze
GB201211310D0 (en) CSF-1R kinase inhibitors
HK1222644A1 (zh) 種可作為表皮生長因子受體激酶抑制劑的鹽式
AU2013201520B9 (en) Solid forms of an epidermal growth factor receptor kinase inhibitor

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF ADDRESS OF PROPRIETOR FROM AON HOUSE, 30 WODDBOURNE AVENUE, PEMBROKE, BERMUDA HM 08, UNITED STATES/UNITED STATES OF AMERICA TO AON HOUSE, 30 WOODBOURNE AVENUE, PEMBROKE HM 08, BERMUDA

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230312